Evidence map›Paper›PMID 36365251›Full record

ReviewPharmaceutics2022

Physically Acting Treatments for Head Lice-Can We Still Claim They Are 'Resistance Proof'?

Ian F Burgess

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ian F BurgessMedical Entomology Centre, Insect Research & Development Limited, 6 Quy Court, Colliers Lane, Stow-cum-Quy, Cambridge CB25 9AU, UK.ORCID 0000-0003-0747-3938

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head lice worldwide have developed resistance to insecticides, prompting the introduction of a range of alternative treatments including plant extracts and natural and synthetic oils. Clinical studies of physically acting treatments showed them to be highly effective when first introduced, and a widely held, but unsubstantiated, belief is that lice are unlikely to develop resistance to them. However, this ignores possibilities for natural selection of traits enabling lice to survive exposure. More recent investigations of some physically acting products have shown reduced efficacy, suggesting either changes of behavior, physical structure, or physiology of some louse populations. In addition, the activity of surfactants and similar compounds, acting as solubilizing agents of insect cuticular lipids, can be compromised by the widespread use of toiletry products containing similar substances. Hitherto, most clinical investigations have provided "best case" data resulting from investigator application of treatments. In the few studies involving participant application, the effectiveness was reduced, suggesting that consumer use allows some insects to survive, which could then be selected for tolerance. Unlike neurotoxic insecticides, there is no straightforward method to test for the activity of physically acting chemicals other than by clinical investigations, which need to be rigorous to eliminate poorly effective products as a way of ensuring the continued effectiveness of those treatments that are successful in eliminating infestation.

Indexed as

clinical trialsessential oilshead liceinsecticidesresistancesiliconessurfactantstreatment

Identifiers

PMID36365251
PMCPMC9695066
OpenAlexW4308771399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.